When should an apolipoprotein B (ApoB) test be ordered and what other lipid and inflammatory markers should be assessed?

Clinical Indications for Apolipoprotein B Testing

Order ApoB when triglycerides are ≥1.5 mmol/L (≥150 mg/dL), as it becomes the preferred screening and treatment target over LDL-C in this setting. 1, 2

Primary Indications for ApoB Testing

Mandatory Situations

• Hypertriglyceridemia (triglycerides ≥1.5 mmol/L): LDL-C becomes unreliable due to triglyceride enrichment of LDL particles and increased small dense LDL production. ApoB or non-HDL-C must replace LDL-C as the primary lipid parameter 1, 2
• Very low LDL-C levels (<70 mg/dL): Friedewald calculation becomes increasingly inaccurate, making ApoB measurement more reliable 1
• Metabolic syndrome, type 2 diabetes, or obesity: These conditions frequently show discordance between LDL-C and ApoB, with ApoB better reflecting true atherogenic particle burden 1, 2

Risk Enhancement Situations

• Family history of premature ASCVD (males <55 years, females <65 years) 1, 3
• Personal history of ASCVD not explained by major risk factors 1
• Suspected familial hyperlipidemia: ApoB aids in diagnosis and enables family cascade screening 1, 4
• Borderline-to-intermediate 10-year ASCVD risk (5-19.9%) when risk-enhancing factors are present 5, 3

Risk-Enhancing Threshold

ApoB ≥130 mg/dL (≥1.3 g/L) constitutes a risk-enhancing factor and corresponds to LDL-C ≥160 mg/dL 5, 1, 3

Other Essential Markers to Assess

Lipoprotein(a) [Lp(a)]

Measure Lp(a) once in lifetime for:

• Family history of premature ASCVD 5, 1
• Parent or sibling with elevated Lp(a) 6
• Personal history of premature ASCVD or stroke without obvious risk factors 5, 1
• Confirmed or suspected familial hypercholesterolemia 6
• Less-than-expected LDL-C reduction with statins 5

Risk-enhancing threshold: Lp(a) ≥50 mg/dL or ≥125 nmol/L 5, 1

Key considerations:

• Lp(a) is genetically determined and stable throughout adult life—measure only once 5, 2
• No fasting required 5, 7
• Use assays calibrated in nmol/L traceable to WHO/IFCC standards 7, 6
• In children, Lp(a) increases throughout childhood/adolescence by approximately 21% from age 8-18 years 6

Standard Lipid Panel Components

Always include:

• Non-HDL-C (total cholesterol minus HDL-C): Preferred over LDL-C when triglycerides >1.5 mmol/L 2

  • Target for high-risk: <2.40 mmol/L (secondary prevention) 7
  • Superior to LDL-C for predicting CVD risk and therapy benefit 6, 2

• Triglycerides:

  • Fasting threshold: <1.7 mmol/L (<150 mg/dL) 7
  • Non-fasting acceptable: <2.0 mmol/L 7
  • Levels ≥1.5 mmol/L trigger need for ApoB or non-HDL-C instead of LDL-C 7, 2

• HDL-C:

  • Low HDL-C (<1.0 mmol/L males, <1.3 mmol/L females) is part of metabolic syndrome criteria 7
  • Strong independent negative predictor of coronary heart disease 8

• Total cholesterol: Use for screening and risk stratification; flag when >5.20 mmol/L 7

Secondary Targets and Ratios

After achieving primary targets, consider:

• TC/HDL-C ratio <4.0 8
• ApoB/ApoA1 ratio <0.80 8, 9
  • This ratio showed highest diagnostic value for acute coronary syndrome in premature CAD (AUC 0.795) 9

Inflammatory Markers (Selected Situations)

High-sensitivity CRP (hs-CRP):

• Consider when risk decision is uncertain 3
• Risk-enhancing threshold: ≥2.0 mg/L 5, 3
• Target <2.0 mg/L in high-risk patients 8

Clinical Algorithm for Lipid Testing

1. Initial screening: Standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)

   • Fasting not required for most situations 1
   • Fasting required for: suspected familial hyperlipidemia, triglycerides >4.52 mmol/L (Friedewald), or when diagnosis/pharmacotherapy decisions needed 1, 7

2. If triglycerides ≥1.5 mmol/L: Order ApoB or use non-HDL-C as primary parameter 2

3. If any of the following present, add ApoB:

   • Metabolic syndrome, diabetes, obesity
   • Very low LDL-C (<70 mg/dL) on therapy
   • Discordance between LDL-C and non-HDL-C
   • Family history of premature ASCVD

4. Add Lp(a) once if:

   • Family history of premature ASCVD
   • Unexplained ASCVD or stroke
   • Familial hypercholesterolemia suspected
   • Suboptimal statin response

5. Consider hs-CRP when risk stratification is uncertain in borderline-intermediate risk patients 3

Critical Pitfalls to Avoid

• Do not rely on LDL-C when triglycerides ≥1.5 mmol/L—it systematically underestimates atherogenic burden 2, 10
• Do not repeat Lp(a) testing—it's genetically determined and stable in adults 5, 2
• Do not use Friedewald LDL-C calculation when triglycerides >4.52 mmol/L—recollect fasting or use alternative equations 7
• Do not assume normal LDL-C means low risk in patients with metabolic syndrome or diabetes—ApoB frequently reveals hidden atherogenic particle excess 4, 11
• Do not measure Lp(a) in children for treatment decisions—no approved therapies exist, though it may inform lifestyle interventions 6

Why ApoB Matters

ApoB represents the total number of atherogenic particles (LDL, VLDL, remnants, Lp(a)—each containing one ApoB molecule). When ApoB and LDL-C are discordant, cardiovascular risk consistently aligns with ApoB, not LDL-C 4, 11. Even 2% discordance between ApoB and LDL particle number significantly increases MACE risk (HR 1.1) 11. This superiority is most pronounced in hypertriglyceridemia, where small dense LDL particles proliferate but carry less cholesterol per particle, causing LDL-C to underestimate true particle burden 1, 2, 10.